Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial
Home
Publications
Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial
Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial
Authors:
KI
Koji Izutsu
Koji Izutsu
KI
Kenji Ishitsuka
Kenji Ishitsuka
DM
Dai Maruyama
Dai Maruyama
KT
Kunihiro Tsukasaki
Kunihiro Tsukasaki
SK
Shigeru Kusumoto
Shigeru Kusumoto
YK
Yasuyuki Kakurai
Yasuyuki Kakurai
HY
Hideyuki Yamauchi
Hideyuki Yamauchi
AI
Ai Inoue
Ai Inoue
MT
Masaya Tachibana
Masaya Tachibana
ST
Shinji Tsutsumi
Shinji Tsutsumi
KT
Kensei Tobinai
Kensei Tobinai
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Open Access
Publisher website
Google Scholar
2 November 2023
journal article
abstracts
Published by
American Society of Hematology
in
Blood
Vol. 142
(Supplement)
,
1731
DOI:
10.1182/blood-2023-179301
Abstract
Disclosures. Izutsu:MSD: Honoraria, Research Funding; Chugai Pharma: Honoraria, Research Funding; Kyowa Kirin: Honoraria, Research Funding; Zenyaku Kogyo: Consu
Keywords
TRIAL DISCLOSURES
RESEARCH FUNDING
PRIMARY RESULTS
B-CELL LYMPHOMAS
REFRACTORY B-CELL
HONORARIA
CHUGAI PHARMA
KYOWA KIRIN
ZENYAKU KOGYO
RESEARCH
Related articles
Cited
Cited by 4 articles
Scroll to top